19,897 results match your criteria Breast Cancer and HER2


In Vitro Vascularized Tumor Platform for Modeling Tumor-Vasculature Interactions of Inflammatory Breast Cancer.

Biotechnol Bioeng 2020 Jul 10. Epub 2020 Jul 10.

Department of Biomedical Engineering, The University of Texas at Austin, TX, USA.

Inflammatory breast cancer (IBC), a rare form of breast cancer associated with increased angiogenesis and metastasis, is largely driven by tumor-stromal interactions with the vasculature and the extracellular matrix (ECM). However, there is currently a lack of understanding of the role these interactions play in initiation and progression of the disease. In this study, we developed the first three-dimensional, in vitro, vascularized, microfluidic IBC platform to quantify the spatial and temporal dynamics of tumor-vasculature and tumor-ECM interactions specific to IBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bit.27487DOI Listing

Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

Department of Radiation Oncology, Max Superspecialty Hospital, Vaishali, Ghaziabad, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05790-4DOI Listing

Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.

Breast Cancer Res Treat 2020 Jul 9. Epub 2020 Jul 9.

Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (Unit 1464), Houston, TX, 77030, USA.

Purpose: Approximately 70% of patients with metastatic breast cancer (MBC) are hormone receptor (HR)-positive. Recent studies have shown that CDK4/6 inhibitors (CDKI) improve survival in combination with ET in HR-positive, HER2-negative MBC. The risk of venous thromboembolism (VTE) is 3-4 times higher in patients with breast cancer (BC) than in patients without cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05783-3DOI Listing

Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.

Oncology (Williston Park) 2020 May;34(5):176-182

Robert H. Lurie Comprehensive Cancer Center, Feingberg School of Medicine, Northwestern University, Chicago, IL.

Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset of patients. TNBC remains a clinical challenge, given the lack of effective targeted treatments such as endocrine therapy for hormone receptor-positive (HR+) tumors or therapies against HER2. Read More

View Article

Download full-text PDF

Source

Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.

JAMA Netw Open 2020 Jul 1;3(7):e207213. Epub 2020 Jul 1.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.

Importance: It is not well understood whether prognostic factors in breast cancer are affected by specific treatment and vary by clinical outcome type compared with untreated patients.

Objective: To identify independent clinical and molecular measurements associated with overall survival (OS) and recurrence-free survival (RFS) by homogeneous treatment in women with breast cancer.

Design, Setting, And Participants: This prognostic study included 956 patients diagnosed with invasive breast cancer from hospital centers across 4 geographical regions of the United States who participated in the accreditation program of the Commission on Cancer of the American College of Surgeons from 1985 to 1997. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2020.7213DOI Listing

Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients.

BMJ Open 2020 Jul 8;10(7):e035389. Epub 2020 Jul 8.

Faculty of Economics and Business (FEB), KU Leuven, Leuven, Flanders, Belgium.

Objectives: Using a standardised diagnostic and generic treatment path for breast cancer, and the molecular subtype perspective, we aim to measure the impact of several patient and disease characteristics on the overall treatment cost for patients. Additionally, we aim to generate insights into the drivers of cost variability within one medical domain.

Design, Setting And Participants: We conducted a retrospective study at a breast clinic in Belgium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2019-035389DOI Listing

Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines.

Cancers (Basel) 2020 Jul 6;12(7). Epub 2020 Jul 6.

Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, TWIns 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo 162-8480, Japan.

HER2 is overexpressed in 25-30% of breast cancers, and approximately 30% of HER2-positive breast cancers metastasize to the brain. Although the incidence of brain metastasis in HER2-positive breast cancer is high, previous studies have been mainly based on cell lines of the triple-negative subtype, and the molecular mechanisms of brain metastasis in HER2-positive breast cancer are unclear. In the present study, we performed intracranial injection using nine HER2-positive breast cancer cell lines to evaluate their proliferative activity in brain tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071811DOI Listing

Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT.

Rev Assoc Med Bras (1992) 2020 May 3;66(5):673-679. Epub 2020 Jul 3.

Department of Nuclear Medicine, Istanbul Training and Research Hospital, University of Health and Sciences, Istanbul, Turkey.

OBJECTIVE Analyze the over expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD-9) deregulated associated with a poor prognosis in various carcinomas. Our objective was to investigate the relationship between the levels of NEDD-9, CA 15-3, and CEA and PET (SUVmax, MTV40, TLG40) with the clinical parameters of patients with breast cancer (BC). METHODS One hundred and eleven patients (82 BC patients who underwent 18F-FDG PET/CT and 29 healthy controls) were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1806-9282.66.5.673DOI Listing

Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.

Breast Cancer Res Treat 2020 Jul 7. Epub 2020 Jul 7.

Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12., CH-8091, Zurich, Switzerland.

Purpose: Human epidermal growth factor-receptor-2 (HER2) is a membrane-tyrosine-kinase that is amplified/overexpressed up to 20% in breast cancer. HER2 positive status is associated with faster disease progression, higher metastatic potential, and shorter disease-free/overall survival and also has emerged as an important therapeutic target in breast cancer. HER2 status can be determined by in-situ-hybridization (ISH) or immunohistochemistry (IHC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05772-6DOI Listing

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.

Breast Cancer Res Treat 2020 Jul 7. Epub 2020 Jul 7.

Department of Breast Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China.

Purpose: Despite the therapeutic success of existing HER2-targeted therapies, tumors respond quite differently to them. This study aimed at figuring out genetic mutation profile of Chinese HER2-positive patients and investigating predictive factors of neoadjuvant anti-HER2 responses.

Methods: We employed two cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05778-0DOI Listing

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event.

Front Oncol 2020 19;10:985. Epub 2020 Jun 19.

Molecular Pathology Research Center, Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

For breast cancer, accurately illustrating HER2 characteristics is a critical precondition for evaluating the prognosis and predicting the efficacy of anti-HER2 therapy. Our purpose was to expose HER2 mRNA expression through an hybridization assay (RNAscope), to aid the identification of HER2 status in breast cancers with a previously controversial classification for patients suffering from a HER2 IHC2+ and HER2/CEP17 ≥2.0 and a <4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318106PMC

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.

Int J Breast Cancer 2020 20;2020:3759179. Epub 2020 Jun 20.

University of Arizona College of Pharmacy, Tucson, AZ, USA.

PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in -mutant, hormone receptor positive (HR+) BC versus ET alone; thus, better understanding the clinical and epidemiologic elements of these mutations is warranted. This systematic review characterizes the mutation epidemiology, type of testing approaches (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/3759179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322582PMC

Neratinib-Induced Duodenal Ulcer: A Case Report.

Breast Cancer (Auckl) 2020 23;14:1178223420935871. Epub 2020 Jun 23.

Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.

We report a case of a 37-year-old woman who developed a duodenal ulcer while receiving adjuvant neratinib for HER2 positive breast cancer. The clinical course of abdominal pain was strongly correlated with the use of neratinib. An esophagogastroduodenoscopy (EGD) was performed and confirmed the diagnosis of a large duodenal ulcer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1178223420935871DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315670PMC

Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells.

Breast Cancer (Auckl) 2020 24;14:1178223420924634. Epub 2020 Jun 24.

Division of Pharmaceutical, Administrative and Social Sciences, Graduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.

A novel melatonin, estrogen, and progesterone hormone therapy was developed as a safe bio-identical alternative hormone therapy for menopausal women based on the Women's Health Initiative findings that PremPro™ increased breast cancer risk and mortality of all types of breast cancer in postmenopausal women. For HER2 breast cancer, melatonin, estrogen, and progesterone delayed tumor onset and reduced tumor incidence in female mice. For other breast cancers, its actions are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1178223420924634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318814PMC

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience.

Ther Clin Risk Manag 2020 30;16:607-615. Epub 2020 Jun 30.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China.

Background: Fulvestrant (FUL) and the combination of everolimus and exemestane (EVE-EXE) were the options to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients who were refractory to aromatase inhibitors (AIs). The practical knowledge of treatment patterns and outcomes between the two regimens is essential for improving treatment decisions.

Methods: HR+/HER2- MBC patients, who were refractory to AI, were treated with FUL or EVE-EXE from June 2013 to June 2016 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/TCRM.S255365DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335268PMC

Histopathologic features of breast cancer in Li-Fraumeni syndrome.

Mod Pathol 2020 Jul 7. Epub 2020 Jul 7.

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Breast cancer is the most common malignancy in female patients with Li-Fraumeni syndrome (LFS), a rare autosomal dominant hereditary syndrome characterized by germline TP53 mutations. Recent studies have shown that the majority of these tumors are estrogen receptor (ER) positive with frequent HER2 co-expression. However, the morphologic features of these tumors have not been as well studied as other germline-associated breast cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0610-4DOI Listing

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

Eur J Cancer 2020 Jul 4;136:43-51. Epub 2020 Jul 4.

Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy; Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy. Electronic address:

Background: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes.

Methods: Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.05.007DOI Listing

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.

Ann Oncol 2020 Jul 4. Epub 2020 Jul 4.

Department of Medical Oncology, Guy's Hospital and Sarah Cannon Research Institute, London, UK.

Background: Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of patients in small clinical series.

Patients And Methods: KAMILLA is an ongoing, phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic breast cancer (MBC) with prior HER2-targeted therapy and chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.020DOI Listing

Immunohistological Expression of Estrogen Receptor, Progesterone Receptor, Mammaglobin, HER2/neu, and GATA3 in Non-Small Cell Lung Cancer.

Histopathology 2020 Jul 7. Epub 2020 Jul 7.

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Objective: Non-small cell lung cancer (NSCLC) and breast cancer are frequent entities. Estrogen receptor (ER), progesterone receptor (PgR), mammaglobin (MAMG), and GATA binding protein 3 (GATA3) are frequently stained to validate a mammary origin in the appropriate diagnostic setting. However, comprehensive data about the immunohistological expression of these markers in NSCLC is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14203DOI Listing

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.

Future Oncol 2020 Jul 7. Epub 2020 Jul 7.

Scientific Department, SOLTI Breast Cancer Research Group, Barcelona, Spain.

New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0246DOI Listing

ASO Author Reflections: MicroRNA-Based Nomogram for Prediction of Sentinel Lymph Node Metastasis in ER+/HER2- Breast Cancer in Hoping for a Possible Omission of Sentinel Lymph Node Biopsy.

Ann Surg Oncol 2020 Jul 6. Epub 2020 Jul 6.

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08797-9DOI Listing

Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.

Horm Cancer 2020 Jul 6. Epub 2020 Jul 6.

Laboratory of Molecular Mechanisms of Carcinogenesis and Molecular Endocrinology, Instituto de Biología y Medicina Experimental (IBYME), CONICET, Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina.

The hormone receptor-positive (estrogen and/or progesterone receptor (PR)-positive) and HER2-negative breast cancer (BC) subtype is a biologically heterogeneous entity that includes luminal A-like (LumA-like) and luminal B-like (LumB-like) subtypes. Decreased PR levels is a distinctive biological feature of LumB-like tumors. These tumors also show reduced sensitivity to endocrine therapies and poorer prognosis than LumA-like tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-020-00392-4DOI Listing

Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.

Medicine (Baltimore) 2020 Jul;99(27):e20808

Department of Basic Medical Science, the Center of Translational Medicine.

Rationale: Palbociclib (PAL) is a first-in-class selective inhibitor of the cyclin-dependent kinases 4 (CDK4) and CDK6 and is indicated for the treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in combination with fulvestrant (FUL) in postmenopausal women. Antrodia cinnamomea (AC), a well-known Chinese folk medicine in Taiwan, possesses numerous biological capabilities, most notably an anti-tumor effect. However, the clinical use of AC as complementary medicine combined with adjuvant therapy is unexplored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020808DOI Listing

ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol.

JCO Glob Oncol 2020 Jul;6:983-990

Center for Global Health, University of Chicago, Chicago, IL.

Human epidermal growth factor receptor 2 (HER2) subtype of breast cancer is aggressive, leading to a poor outcome. Targeted therapy with trastuzumab has been shown to be effective in the treatment of HER2-positive breast cancer. Cardiotoxicity is a specific adverse effect associated with trastuzumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/GO.20.00043DOI Listing

High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.

Int J Oncol 2020 Aug 10;57(2):488-499. Epub 2020 Jun 10.

Department of Burns and Plastic Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, Guangdong 510220, P.R. China.

Breast cancer is the most common malignant tumor affecting women worldwide and is divided into the following subtypes: Luminal A, Luminal B, HER‑2 overexpression and triple‑negative breast cancer (TNBC). TNBC accounts for approximately 15‑20% of all breast cancer cases. Due to the characteristics of low differentiation, the likelyhood of recurrence and metastasis, strong invasiveness and the lack of hormone receptors and human epidermal growth factor receptor 2 (HER2), patients with TNBC cannot benefit from endocrine therapy or other available targeted agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2020.5080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307591PMC

Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer.

Breast 2020 Jun 26;53:44-50. Epub 2020 Jun 26.

Medical Oncology Unit. Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Breast Cancer Unit. Institut Català D'Oncologia, Hospital Moisès Broggi. Sant Joan Despí, Barcelona, Spain. Electronic address:

Metastatic breast cancer (MBC) diagnosis in young women negatively impacts on quality of life (QoL) and daily activities, disrupting their life project and forcing them to face new psychosocial challenges. The recently published results on the improvement of the overall survival of pre- or perimenopausal women with hormone-receptor-positive, HER2-negative MBC treated with CDK4/6 inhibitors plus endocrine therapy, while preserving, and in some items improving their QoL, will change the landscape of the management of this patient population. Their extended survival and potential improvement in QoL will, therefore, modify their specific needs in terms of psychosocial support. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2020.06.007DOI Listing

Receptor discordance and phenotype change in metastatic breast cancer.

Asian J Surg 2020 Jul 1. Epub 2020 Jul 1.

Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138, Sheng-Li Road, Tainan, 70428, Taiwan; Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 345, Jhuangjing Road, Dou-Liou, 64043, Taiwan. Electronic address:

Background: changes may occur in tumor phenotype and receptor status during the progression of breast cancer. Discordance between primary and metastases has implications for further treatment and prognosis.

Methods: 185 patients confirmed breast cancer metastasis were retrospectively analyzed during 1999-2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.asjsur.2020.05.032DOI Listing

Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.

Cancer Treat Rev 2020 Jun 24;88:102064. Epub 2020 Jun 24.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.

The overexpression of human epidermal growth factor receptor-2 (HER2) results in a biologically and clinically aggressive breast cancer (BC) subtype. Since the introduction of anti-HER2 targeted agents, survival rates of patients with HER2-positive metastatic BC have dramatically improved. Currently, although the treatment decision process in metastatic BC is primarily based on HER2 and hormone-receptor (HR) status, a rapidly growing body of data suggests that several other sources of biological heterogeneity may characterize HER2-positive metastatic BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102064DOI Listing

Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.

Breast Cancer Res Treat 2020 Jul 3. Epub 2020 Jul 3.

Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.

Purpose: The prognostic role of tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer (BC) is debated. We evaluated the association of TILs and clinico-pathological features with distant disease-free survival (DDFS) in patients with ER+/HER2- BC treated at a single institution.

Patients And Methods: A mono-institutional case-cohort series of 987 patients with early ER+/HER2- BC was retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05771-7DOI Listing

Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.

Pathol Oncol Res 2020 Jul 3. Epub 2020 Jul 3.

Department of Pathology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.

Amplicon-based next generation sequencing (NGS) approaches have been preferentially adopted by the clinical laboratories on the basis of a short turnaround time (TAT) and small DNA input needs. However, little work has been done to assess the amplicon-based NGS methods for copy number variation (CNV) detection in comparison with current standard methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The correlation between NGS based CNV detection and the later standard methods has remained unexplored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-020-00844-wDOI Listing
July 2020
1.806 Impact Factor

Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.

Mod Pathol 2020 Jul 3. Epub 2020 Jul 3.

Department of Pathology, The University of Alabama Birmingham, Birmingham, AL, USA.

Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status provide clinical utility in guiding therapeutic decision-making in metastatic breast cancer (BC). Increasing data have shown substantial differences between the receptor profiles of primary BCs and their paired metastases. In this study, we provide a large single center cohort to assess the frequency of receptor conversion in metastatic BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0615-zDOI Listing

Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.

Anticancer Res 2020 Jul;40(7):3973-3981

Gynecology and Obstetrics Department, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Background/aim: HER2-positive breast cancers eventually relapse in about one third of patients. Is anti-HER2-directed therapy with Herceptin® (trastuzumab) effective in re-treatment? Between 2008 and 2018, 216 patients with recurrent HER2-positive breast cancer (BC) were re-treated with Herceptin (HER) during first-line therapy. This study assessed the effectiveness and tolerability of re-treatment with HER. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14390DOI Listing

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.

Anticancer Res 2020 Jul;40(7):3905-3913

Biostatistics Department, Centre Léon Bérard, Lyon, France.

Background/aim: Vinorelbine is indicated for use in the treatment of MBC as a single agent or in combination but there is little real world data on this molecule and even less on its oral form. We exploited the Unicancer Epidemiology Strategy Medical-Economics (ESME) metastatic breast cancer (MBC) database to investigate current patterns of use of oral vinorelbine (OV), as well as outcomes of patients receiving this drug.

Patients And Methods: Data were collected retrospectively from women and men treated for MBC between 2008 and 2014 at one of 18 French Comprehensive Cancer Centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14381DOI Listing

Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.

Anticancer Res 2020 Jul;40(7):3669-3683

Division of Biochemical Toxicology, FDA/NCTR, Jefferson, AR, U.S.A.

Background/aim: Triple negative cancer (TNBC) is a subtype of breast cancer that is highly aggressive, with poor prognosis and responds differently to treatments. This study investigated the role of vorinostat and indole-3-carbinol (I3C) on regulating critical receptors that are not normally expressed in TNBC.

Materials And Methods: Using real-time PCR, immunostaining, and western blots, the re-expression of estrogen receptor α (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) receptors was examined in four different TNBC cell types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14356DOI Listing

Is There Any Association Between Mammographic Features of Microcalcifications and Breast Cancer Subtypes in Ductal Carcinoma In Situ?

Acad Radiol 2020 Jun 30. Epub 2020 Jun 30.

Department of General Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey.

Rationale And Objectives: To analyze the association between mammographic features of microcalcifications and histopathological prognostic factors based on estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2/neu) in ductal carcinoma in situ (DCIS).

Materials And Methods: We retrospectively determined 66 patients with microcalcification-associated pure DCIS. Distribution and morphological features of the microcalcifications were described using Breast Imaging Reporting and Data System lexicon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2020.05.032DOI Listing

Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.

BMC Med Genomics 2020 Jul 3;13(1):92. Epub 2020 Jul 3.

Data Science Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.

Background: The role of histone modifications is poorly characterized in breast cancer, especially within the major subtypes. While epigenetic modifications may enhance the adaptability of a cell to both therapy and the surrounding environment, the mechanisms by which this is accomplished remains unclear. In this study we focus on the HER2 subtype and investigate two histone trimethylations that occur on the histone 3; the trimethylation located at lysine 4 (H3K4me3) found in active promoters and the trimethylation located at lysine 27 (H3K27me3) that correlates with gene repression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-020-00749-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333309PMC

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.

Cancer Treat Res Commun 2020 Jun 27;24:100188. Epub 2020 Jun 27.

Medical Oncology, Royal Marsden Hospital, Royal Marsden Hospital, Downs Road, Sutton SM25PT, United Kingdom. Electronic address:

Background: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated its safety and efficacy in our real-world population.

Methods: We identified patients on T-DM1 from 01/01/2014 to 12/03/2018 from our electronic records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100188DOI Listing

Performance of preoperative breast MRI based on breast cancer molecular subtype.

Clin Imaging 2020 May 27;67:130-135. Epub 2020 May 27.

Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address:

Purpose: To assess the performance of preoperative breast MRI biopsy recommendations based on breast cancer molecular subtype.

Methods: All preoperative breast MRIs at a single academic medical center from May 2010 to March 2014 were identified. Reports were reviewed for biopsy recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2020.05.017DOI Listing

Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.

Oncologist 2020 Jul 3. Epub 2020 Jul 3.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Background: The integration of residual cancer burden (RCB) and post-treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long-term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared with RCB. However, no specific analysis in hormone-receptor-positive (HR+) human epidermal growth receptor 2-negative (HER2-) BC is available so far.

Materials And Methods: A cohort of 130 patients with HR + HER2- BC who underwent NACT between 2000 and 2014 was included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0201DOI Listing

Systems biology comprehensive analysis on breast cancer for identification of key gene modules and genes associated with TNM-based clinical stages.

Sci Rep 2020 Jul 2;10(1):10816. Epub 2020 Jul 2.

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Breast cancer (BC), as one of the leading causes of death among women, comprises several subtypes with controversial and poor prognosis. Considering the TNM (tumor, lymph node, metastasis) based classification for staging of breast cancer, it is essential to diagnose the disease at early stages. The present study aims to take advantage of the systems biology approach on genome wide gene expression profiling datasets to identify the potential biomarkers involved at stage I, stage II, stage III, and stage IV as well as in the integrated group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67643-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331704PMC

Bispecific antibodies: a novel approach for targeting prominent biomarkers.

Hum Vaccin Immunother 2020 Jul 2:1-9. Epub 2020 Jul 2.

Division of Biological Sciences and Engineering, Netaji Subhas University of Technology (NSUT) , New Delhi, India.

Many types of cancers are prevalent in India and worldwide. Monoclonal antibodies (MAbs) are one of the major types of cancer therapeutics, which have included MAbs of hybridoma, chimeric, humanized, or human origin. MAbs are mostly generated currently by direct cloning from B cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2020.1738167DOI Listing

Analysis of Clinical-Pathological Data with Impact on Overall Survival in Male Breast Carcinoma: An International Multi-Institutional Study of 217 Cases.

Chirurgia (Bucur) 2020 May-Jun;115(3):323-333

The aim of this study was to evaluate clinical-pathological parameters with impact on overall survival (OS) in male breast carcinoma (MBC). Methodology: We assessed OS at 5 years and at 10 years respectively, as well as OS according to age, tumor size, microscopic type, histological grade, axillary lymph node status, and molecular profile. Two hundred seventeen cases, with a mean age of 62 (range: 18- 85), right breast involvement (52. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21614/chirurgia.115.3.323DOI Listing

Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?

Future Oncol 2020 Jul 2. Epub 2020 Jul 2.

Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.

Despite advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, the disease is rarely curable. In this review, we focus on the use of cyclin-dependent kinase (CDK) 4/6 inhibitors, examining clinical experience and the mechanisms underlying the development of resistance, and evaluating treatment options after failure to respond to CDK4/6 inhibitors. Current basic research supports the use of mammalian target of rapamycin inhibitors after CDK4/6 inhibitor failure; however, more data are needed, particularly regarding treatment sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0326DOI Listing

Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database.

Neoplasma 2020 Jul 2. Epub 2020 Jul 2.

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Triple-positive breast cancer (TPBC), i.e. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2020_191023N1080DOI Listing

Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.

ACS Appl Mater Interfaces 2020 Jul 10. Epub 2020 Jul 10.

School of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, P. R. China.

siRNA therapeutics as an emerging class of drug development is successfully coming to clinical utilization. The RNA-based therapy is widely utilized to explore the mechanism and cure a variety of gene-specific diseases. Tumor is an oncogene-driven disease; many genes are related to tumor progression and chemoresistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.0c07353DOI Listing

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

Breast Cancer Res Treat 2020 Jul 1. Epub 2020 Jul 1.

Department of Obstetrics and Gynecology, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.

Background: The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications.

Patients And Methods: In all, 541 patients with available receptor statuses from both primary tumor and metastatic lesion treated at Heidelberg and Tuebingen University Hospitals between 1982 and 2018 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05746-8DOI Listing

Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer?

Ann Surg Oncol 2020 Jul 1. Epub 2020 Jul 1.

Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Background: The Society of Surgical Oncology's Choosing Wisely guidelines recommend against routine sentinel lymph node biopsy (SLNB) in clinically node-negative (cN0), hormone receptor (HR)-positive breast cancer patients aged ≥ 70 years. We examined the effect of SLNB on treatment and outcomes in this population.

Materials And Methods: A single-institution retrospective review of consecutive cN0 women ≥ 70 years of age who received SLNB was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08759-1DOI Listing

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer.

Front Oncol 2020 16;10:968. Epub 2020 Jun 16.

Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.

The PI3K/Akt/mTOR pathway in part impacts tumorigenesis through modulation of host immune activity. To assess the effects of Akt inhibition on the tumor micro-environment (TME), we analyzed tumor tissue from patients with operable hormone receptor positive, HER2 negative breast cancer (BC) treated on a presurgical trial with the Akt inhibitor MK-2206. Quantitative multiplex immunofluorescence (qmIF) was performed using CD3, CD8, CD4, FOXP3, CD68, and pancytokeratin on biopsy and surgical specimens of MK-2206 and untreated, control patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308467PMC

Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.

Front Oncol 2020 16;10:950. Epub 2020 Jun 16.

Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.

Immunohistochemistry (IHC) for ER, PR, HER2, and Ki67 is used to predict outcome and therapy response in breast cancer patients. The current IHC assessment, visual or digital, is based mostly on global biomarker expression levels in the tissue sample. In our study, we explored the prognostic value of digital image analysis of conventional breast cancer IHC biomarkers supplemented with their intratumoral heterogeneity and tissue immune response indicators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00950DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308549PMC

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.

Sci Rep 2020 Jul 1;10(1):10757. Epub 2020 Jul 1.

Oncology Department, Centre Léon Bérard, Lyon, France.

Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metastatic breast cancer. We conducted a secondary analysis of the national, multicentric, non-randomized, prospective cohort SNPs to Risk of Metastasis (StoRM) study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67431-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329808PMC